• Introduction
• 16 min
  1. Psychopharmacology: structural aspects of the brain

  • Prof. Brian Leonard
• 66 min
  2. The nature of chemical neurotransmission

  • Prof. Brian Leonard
• 28 min
  3. Psychotropic drugs

  • Prof. Brian Leonard
• 26 min
  4. Psychopharmacology of anxiety disorders

  • Prof. Brian Leonard
• 35 min
  5. Psychopharmacology of depression

  • Prof. Brian Leonard
• 48 min
  6. Psychopharmacology of mania and schizophrenia

  • Prof. Brian Leonard
• 45 min
  7. The role of stress and immune system in psychiatric disorders

  • Prof. Brian Leonard
• Introduction to Genetic Investigations of Complex Traits
• 39 min
  8. Genetic association studies, TDT and the candidate gene approach

  • Dr. Jo Knight
• Genetics and Pharmacokinetics of Psychotropic Drugs
• 34 min
  9. Genetics of phase I enzymes

  • Prof. Aiming Yu
• 36 min
  10. Phase II metabolism

  • Prof. Ann Daly
• Genetics and Pharmacodynamics of Psychotropic Drugs
• 25 min
  11. Genetics and psychotropic drugs: present and future clinical applications

  • Dr. Chiara Fabbri
• 25 min
  12. Influence of neurotransmitter receptor variants on interactions with psychotropic drugs

  • Dr. Maria Arranz
• 51 min
  13. Pharmacogenetics of antidepressants

  • Prof. Alessandro Serretti
• Clinical Applications of Psychopharmacogenetics
• 41 min
  14. Of genes and drugs: genetic determinants of adverse drug reactions

  • Dr. Mario Masellis
• 35 min
  15. Cocaine and amphetamine addiction genetics

  • Dr. Gerome Breen
• 29 min
  16. Tailoring psychiatric treatment using genetic information: pharmacogenetic prediction of treatment response

  • Dr. Maria Arranz
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  17. Genetic, environmental and other design issues relevant for pharmacogenetics studies

  • Dr. Ridha Joober
• 37 min
  18. Genetic determinants of metabolism: clinical applications in psychiatry

  • Prof. Julia Stingl (formerly Kirchheiner)
• 36 min
  19. Rapid methods for the genetic determination of pharmacokinetic status

  • Dr. Paul Debenham
• 47 min
  20. Genetic polymorphisms influencing response to lithium

  • Prof. Alessandro Serretti
• 28 min
  21. Genetic determinants of antipsychotic-induced weight gain

  • Prof. Gavin Reynolds
• 59 min
  22. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 1

  • Dr. Vincenzo Basile
• 50 min
  23. Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 2

  • Dr. Vincenzo Basile
• 37 min
  24. Genetic determinants of agranulocytosis

  • Dr. Michael Dettling
• 52 min
  25. Genetic polymorphisms influencing the response of antidepressants

  • Prof. Alessandro Serretti

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Can genes determine complex traits?
3. The human genetics
4. Genetic variation
5. Pharmacogenetics
6. Genetically based optimization of drug dosing
7. Variations in drug response
8. Genetic polymorphisms
9. Polymorphic and polygenic effects on drug action
10. Examples of pharmacogenetics
11. Pharmacogenetics of mood disorders
12. Present and future
13. Is antidepressant response genetically controlled?
14. Pharmacogenetic studies (Medline 1998-2004)
15. Genes involved in response to antidepressants
16. Serotonin transporter
17. Serotonin transporter polymorphism
18. Regulatory variant of 5-HT transporter
19. Serotonin and psychopathology
20. Serotonin transporter and depression
21. Serotonin transporter and other mood disorders
22. 5-HTTLPR and response to fluvoxamine
23. HAMD decrease during fluvoxamine treatment
24. SERT studies in Caucasians
25. SERT studies in Orientals
26. A new polymorphism (A-G) within SERTPR
27. Serotonin transporter promoter (Nakamura, 2000)
28. Variants of long and short repeats
29. Types of 16th repeat (*l)
30. SERTPR *l and *s allele variants
31. Review - pharmacogenetics and antidepressants
32. Genes investigated in the short term
33. Serotonin receptor 1A studies
34. Serotonin receptor 1A
35. G-protein beta 3 subunit studies
36. G-protein beta 3 subunit
37. Serotonin receptor 2A studies
38. Tryptophan hydroxylase
39. Tryptophan hydroxylase studies
40. Polymorphism and antidepressant response
41. Studies with positive but unreplicated results
42. Sufficiency criteria for clinical prediction
43. Negative studies
44. Polymorphisms in FKBP5
45. FKBP5 genotype and depression
46. Methods - procedures
47. Do genetic patterns influence drug response only?
48. Time course
49. Most studies focus on the first weeks of treatment
50. Example for follow-up study
51. Illness time course
52. 6-month follow-up study
53. A follow-up study: methods
54. Towards new classification of psychiatric disorders
55. Is antidepressant response a unitary phenomenon?
56. CLOCK gene
57. Insomnia and CLOCK gene polymorphism
58. CLOCK gene polymorphism
59. CLOCK variants and insomnia during treatment
60. CC variant resist insomnia improvement
61. CLOCK variant in a follow-up study
62. UP and BP subject with *C allele
63. New classification of psychiatric disorders
64. How do genes exert their role?
65. PER gene
66. PER gene characteristics
67. Association with anti-depressant efficacy
68. PER gene and clinical features
69. PER gene and depressive symptoms
70. PER gene and personality
71. PER gene and social impairment
72. Broad influence of PER gene
73. Less common PER gene variants
74. Summary of gene influences
75. Complex gene direct and indirect effects?
76. Novelty seeking (NS) trait
77. Temperament and character in mood disorders
78. Short variant of SERT has less NS
79. Would be the puzzle the actual image of reality?
80. Pharmacogenetics: problematic issues
81. Neural network analysis
82. Neural network analysis in pharmacogenetics
83. Neural network analysis techniques
84. Neural network analysis gives more details
85. HTT, TPH - MLP
86. Technical details on MLP
87. ROC curve of the analysis
88. The significance of the network
89. Comparison with traditional techniques
90. Neural network analysis summary
91. Conclusion
92. Ethical, legal and social implications
93. 2012 update - introduction
94. Pooling Caucasians and Asians separately
95. HTTLPR - conclusions
96. Effects in people with short variant (1)
97. Effects in people with short variant (2)
98. Broad influence of a single gene
99. Genome wide associations - studies
100. Other genes involved in antidepressant
101. Main replicated genes

Topics Covered

• Pharmacogenetic studies in mood disorder
• Candidate genes as possible genetic predictors of antidepressant response efficacy
• Serotonin transporter gene (5-HTTLPR)
• Serotonin receptor 1A (5HT1A-C-1019G)
• G-protein beta3-subunit (Gbeta3-C825T)
• Serotonin receptor 2A (5HT2A
• 102TC)
• Tryptophan hydroxylase gene (TPH-A218C)
• Associations for FKBP5 and other unreplicated gene variants
• Follow up pharmacogenetic studies
• Circadian Locomotor Output Cycles Kaput (CLOCK-T3111C) gene variants are associated with insomnia and other features
• PER 15 variants and mood disorder phenotypes
• Neural networks: the example of 5-HTTLPR and TPH polymorphisms

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on October 1, 2007
• Updated on December 1, 2012
• Archived on October 31, 2024

Financial Disclosures

• Prof. Alessandro Serretti has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.